Features
COVID-19, Vaccines, and Retinal Vascular Disease
A global systematic review of 173 studies found differing associations between COVID-19 infection and vaccination and retinal vascular events, with retinal artery occlusion more common after infection and retinal vein occlusion more common after vaccination.
By Nirojini Sivachandran, MD, PhD, FRCSC
EYP-1901 Approaches a Pivotal Fall
At Retina World Congress, Ashkan M. Abbey, MD, FASRS, FAAO, reviewed the Duravyu clinical development program. Top-line data from the phase 3 LUGANO and LUCIA trials in wet AMD are expected later this year.
By Ashkan M. Abbey, MD
Avoid Aches and Pains in Retina Practice
Simple adjustments to posture, equipment positioning, and workflow can help retina specialists prevent chronic pain.
By Sunir Garg, MD, FACS, FASRS
Managing an Aggressive Case of Placoid Chorioretinopathy
At Retina World Congress, Arthi Venkat, MD, MS, explained how to differentiate ampiginous chorioretinitis from infectious retinitis in a patient with rapid vision loss.
By Arthi Venkat, MD, MS
FDA Updates: Retina Trials and Regulatory Pathways
William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.
By Matthew Solan, senior writer
What RVO May Reveal About Systemic Health
TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.
By Katherine E. Talcott, MD, FASRS
Recognizing MacTel Masquerades
Imaging features such as retinal thinning and ellipsoid zone loss can help differentiate MacTel from AMD and related retinal diseases.
By Jay Chhablani, MD
Can Gene Therapy Deliver Durability?
At Retina World Congress, David A. Eichenbaum, MD, examined whether late-stage intravitreal gene therapies can reduce injection burden in nAMD.
By Jim Gallagher, senior managing editor
Can Home OCT Change nAMD Monitoring?
Courtney Crawford, MD, highlighted clinical data and the Protocol AO trial evaluating home OCT’s impact on monitoring and treatment decisions in AMD.
By Matthew Solan, senior writer







